How much does SOLIRIS (Eculizumab Injection) Cost& price without insurance in China?
SOLIRIS® is the commercial brand name of Eculizumab Injection, a humanized anti-C5 monoclonal antibody developed by Alexion Pharmaceuticals. It binds to complement protein C5, preventing its cleavage into C5a and C5b-9, thereby inhibiting terminal complement-mediated hemolysis and inflammation.
Main Indications
Treatment of paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.
Treatment of atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy.
Treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive.
Common Side Effects
Common mild adverse reactions: Headache, upper respiratory tract infection, diarrhea, nausea, and fatigue.
Severe but uncommon risks: Serious infections (including meningococcal infections, which can be fatal), hypersensitivity reactions, and thromboembolic events.
Approval Status in China
SOLIRIS® (Eculizumab Injection, 300mg/30mL) was officially approved for marketing in China in 2018. It is currently a prescription biologic drug included in China’s National Medical Insurance List.
Buy SOLIRIS (Eculizumab Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
